Hillstar Bio bolsters leadership team as autoimmune pipeline readies for clinic
US biotech Hillstar Bio has appointed Maude Tessier as chief operating officer and Shiva Krupa as vice president of program management, reinforcing its leadership bench ahead of a planned clinical entry for its lead autoimmune program in 2026.
The hires follow the recent departure of Lauren Mifflin, who will continue supporting the business in an advisory role. Mifflin had served as COO while also holding a position at Frazier Life Sciences, one of Hillstar's backers.
Based in Boston, the company is developing precision immunology therapies, including its TRBV9 program aimed at axial spondyloarthritis (AxSpA). That program is expected to enter human trials next year and has become a focal point of Hillstar’s strategy to selectively target harmful immune cells without broadly suppressing the immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze